BridgeBio Pharma vs Travere Therapeutics
BBIO and TVTX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BBIO and TVTX compare
BridgeBio Pharma is the larger company, worth 3.2 times as much as Travere Therapeutics ($15.1B against $4.7B).
BridgeBio Pharma grew revenue faster over the last twelve months (167% versus 77.1% for Travere Therapeutics).
Travere Therapeutics scores higher on the StockData Score (6 against 3 for BridgeBio Pharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BBIO | TVTX |
|---|---|---|
| Size and price | ||
| Market cap | $15.1B | $4.7B |
| Share price | $77.36 | $49.70 |
| Change, 1 year | 18.9% | 46.7% |
| Change, 5 years | 95.6% | 71.2% |
| Beta (5Y) | 0.22 | 1.95 |
| Employees | 834 | 497 |
| StockData Score | ||
| Total score | 3 | 6 (better) |
| Valuation score | 0 | 0 |
| Growth score | 2 | 3 (better) |
| Performance score | 0 | 2 (better) |
| Health score | 1 | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 15.9× | 7.9× (better) |
| P/B | – | 191× |
| EV/EBITDA | – | 192× |
| FCF yield | −2.5% | – |
| Fair value | – | $6.04 |
| Margin of safety | – | −723% |
| Growth | ||
| Revenue growth (TTM) | 167% (better) | 77.1% |
| Revenue growth, 5Y average | 127% (better) | 19.9% |
| Profitability | ||
| Gross margin | 94.3% | 98.6% (better) |
| Operating margin | −38.5% | −6.8% (better) |
| Net margin | – | −7.4% |
| FCF margin | −39.1% | – |
| Return on equity | – | −152% |
| Financial health | ||
| Interest coverage | −7.1× | −4.3× (better) |
| Current ratio | 2.09 | 4.05 (better) |
| Altman Z-score | 0.13 | 2.19 (better) |
| Piotroski F-score | – | 7 |
| Dividends and buybacks | ||
| Buyback yield | 1.7% | – |
| Shareholder yield | 1.7% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 99.4% | 112% |
| Held by insiders | 35.6% | 1.6% |
| Insider net buying, 12 months | −$84.8M (better) | −$110M |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 16.6% | 10.3% |
Go deeper
- BBIO stock overview
- BBIO income statement
- BBIO valuation and score
- TVTX stock overview
- TVTX income statement
- TVTX valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.